Tollys
About:
Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor.
Website: http://tollys.fr/
Top Investors: Investisseurs privés
Description:
Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor. The company is advancing TL-532, a new cancer immunotherapy to treat various types of cancer. TL-532 is a structurally defined double-stranded RNA, produced synthetically and highly specific to the TLR3 receptor.
2.3M EUR
Lyon, Rhone-Alpes, France
2015-01-01
contact(AT)tollys.fr
Jacques-François Martin, Philippe Guillot-Chene
1-10
2020-05-26
Private
© 2025 bioDAO.ai